Does BPC-157 stack well with other therapies at Peak Performance
We did not find your search
Keep all medicine out of the reach of children
McMurray reports payments to his institution for work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardurion, Cytokinetics, Dal-Cor, GSK, lonis, KBP Biosciences, Novartis, Pfizer, and Theracos, as well as personal payments from Abbott, Alkem Metabolics, AstraZeneca, Boehringer Ingelheim, Cardurion, Eris Lifesciences, Hikma, lonis, Lupin, Novartis, ProAdWise Communications, and Sun Pharmaceuticals
Instead of targeting blood flow, PT-141 targets receptors in the brain linked to sexual arousal creating a pathway for increased desire and satisfaction at the source